Journal
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Volume 744, Issue 1, Pages 99-112Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0378-4347(00)00236-X
Keywords
8-isoprostaglandin F-2 alpha; 2,3-dinor-5,6-dihydro-8-isoprostaglandin F-2 alpha
Ask authors/readers for more resources
Whole body synthesis of F-2-isoprostanes, a family of cyclooxygenase-independent eicosanoids formed by free-radical catalysed peroxidation, should be best assessed by quantifying their urinary metabolites. Two methods for the quantitative determination of F-2-isoprostane metabolites in human urine performing either thin-layer chromatography (TLC) (method A) or high-performance liquid chromatography (HPLC) (method B) prior to GC-tandem MS are described. Method A allows for simultaneous quantification of 8-iso-PGF(2 alpha), one prominent member of the F-2-isoprostane family, and its major urinary metabolite, 2,3-dinor-5,6-dihydro-8-iso-PGF(2 alpha). Mean excretion was found to be 223 and 506 pg/mg creatinine of 8-iso-PGF(2 alpha) and 2,3-dinor-5,6-dihydro-8-iso-PGF(2 alpha), respectively (n = 14), A tight correlation existed between the urinary excretion of these two isoprostanes (r = 0.86). Method B enables quantification of dinor-dihydro metabolites of various F-2-isoprostanes including 8-iso-PGF(2 alpha). 2,3-Dinor-5,6-dihydro-8-iso-PGF(2 alpha) was found to be an abundant dinor-dihydro F-2-isoprostane metabolite. Validity of method A was proven by a combination of HPLC with TLC prior to GC-tandem MS analysis. A correlation was observed between the urinary concentrations of 2,3-dinor-5,6-dihydro-8-iso-PGF(2 alpha) measured by GC-MS and GC-tandem MS (r = 0.84). (C) 2000 Elsevier Science BN. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available